Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel (CabB1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01668459|
Recruitment Status : Unknown
Verified January 2013 by Dr Anjali Zarkar, University Hospital Birmingham NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : August 20, 2012
Last Update Posted : January 24, 2013
|Condition or disease||Intervention/treatment||Phase|
|Transitional Cell Carcinoma||Drug: Cabazitaxel Other: Best Supportive Care||Phase 2 Phase 3|
Bladder cancer was the 9th most common cause of cancer worldwide in 2002. About 70% of patients have superficial tumour and 30% have invasive tumour at diagnosis. Patients with superficial tumour are treated by surgery, which is the only curative treatment. However, about 50% of these patients will relapse, and cannot be cured by local treatment in the majority of cases. The survival of untreated metastatic patients does not exceed 3 to 6 months, and systemic chemotherapy increases overall survival of patients with unresectable disease.
However, the overall survival of patients with advanced disease treated with chemotherapy remains short (14 months), which reflects a substantial unmet medical need for more effective therapy in this very poor prognosis disease.
Cabazitaxel is a new taxane, taxanes have demonstrated activity in advanced bladder cancer, and are among the most active new cytotoxic agents to be assessed in transitional cell carcinoma.
Cabazitaxel has demonstrated activity in cell lines with acquired resistance to doxorubicin, vincristine, vinblastine, paclitaxel, and docetaxel.
This is a randomised, open-label, parallel-group phase 2 study of cabazitaxel versus best supportive care (including chemotherapy).
The study is divided into three phases: screening, treatment, and follow-up. The treatment phase comprises a maximum of six three-weekly cycles of therapy, with a post treatment discontinuation visit taking place 3 weeks after last dose of treatment before the follow-up phase begins.
This phase 2 study will initially recruit 25 patients and after interim analysis will to increase to recruit 96 patients randomised between the two treatment options and the study is expected to last about 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||96 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2015|
6 cycles (3 weekly) of 25 mg/m^2 IV infusion
25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
Other Name: Jevtana, XRP6258, RPR116258A
Best Supportive Care
Best supportive care including single agent chemotherapy as determined by the patient's study doctor
Other: Best Supportive Care
Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
- Overall response rate [ Time Frame: Change from baseline at Week 9 and Week 18 ]To compare the overall response rate of patients administered cabazitaxel vs best supportive care (including single agent chemotherapy) in patients with transitional cell carcinoma who have previously progressed on a platinum-based regimen.
- Overall survival [ Time Frame: From date of randomisation to the date of tumour progression or death (from any cause) (or survival at study cut-off date), whichever came first up to 12months after the final patient has completed study treatment ]Defined as the time interval from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time will be censored at the earlier of the last date the patient is known to be alive and the study cut-off date.
- Quality of Life [ Time Frame: Change from baseline at Week 6, Week 12, Week 18, Week 21 ]QOL will be assessed by using a validated instrument; the EuroQOL (EQ-5D).
- Safety and tolerability [ Time Frame: From date of randomisation up to 30 days after final dose of study medication ]Dose delays and dose reductions, adverse events, laboratory safety data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01668459
|Contact: Anjali Zarkar, MD MBBS||+44 121 371 email@example.com|
|Contact: Amanda Davies, BSc (Hons)||+44 121 204 firstname.lastname@example.org|
|University Hospitals Birmingham||Recruiting|
|Birmingham, United Kingdom, B15 2TH|
|Principal Investigator: Anjali Zarkar, MRCP MD FRCR|
|Sub-Investigator: Nicholas James, MBBSFRCP PhD|
|Principal Investigator:||Anjali Zarkar||University Hospitals Birmingham NHS FT|